The main evidence of fraudulent behavior comes from late 2020, when one particular trial site – Site 1231 – rapidly enrolled thousands of participants so that Pfizer can meet a deadline before the Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee (VRBPAC) meets in Dec. 2020 to discuss granting the Big Pharma company emergency use authorization for its COVID-19 vaccine. (Related: JAB 'EM YOUNG: FDA approves Pfizer's booster vaccine for children aged 5 to 11 without consulting vaccine advisory panel.)
Site 1231, located in Argentina, was somehow able to recruit 4,501 participants in just three weeks and without the aid of a contract research organization. These organizations provide clinical trial management services and help lessen the burden pharmaceutical companies have when it comes to administering medical trials.
The recruitment also took place seven days a week, another sign of possible fraud because medical trials are usually understaffed during weekends and would be unable to properly handle prospective participants and all of the forms and tests that they need before being signed on.
It should also be noted that the trial participants in Site 1231 represent around 10 percent of the total trial participants for Pfizer's COVID-19 vaccine.
Furthermore, the lead investigator for Site 1231 is Dr. Fernando Polack. He happens to be a consultant for the VRBPAC. He is also the founder and lead investigator for Fundacion Infant, an Argentine nonprofit organization that researches diseases seriously affecting children. This organization has received extensive funding from the Bill and Melinda Gates Foundation. Polack is also the first author of one of Pfizer's first scientific papers regarding its COVID-19 vaccine.
In addition to all of these roles, Polack, as lead investigator in Site 1231, was also supposedly able to enroll all of the site's 4,501 participants himself, which entails single-handedly filling out some 250 pages of case report forms per participant.
Site 1231 was used for a second enrollment session of the vaccine trial and rechristened as Site 4444. Similar to its previous iteration, Site 4444 also raises red flags in its management of the trial.
Site 4444 was supposedly able to enroll 1,275 new trial participants in a single week from Sept. 22 to 27, 2020. While the speed itself has raised suspicions, the fact that this was the last week that recruitment could take place to meet the data cutoff for the VRBPAC's meeting in December of that year.
With nearly 5,800 participants enrolled, Sites 1231 and 4444 had nearly four times more participants than the next largest trial center.
The speed at which participants were enrolled in Sites 1231 and 4444 makes it likely that Pfizer needed more trial participants to make it look like its COVID-19 vaccine is doing well when in reality it has likely caused more adverse reactions – and possibly even deaths – than it cares to admit.
"Was there fraud in the Pfizer trial? Without a doubt," noted entrepreneur and vaccine researcher Steve Kirsch, one of the first people who broke the story regarding Sites 1231 and 4444.
"This new data on Site 1231/4444 looks suspicious to me. It looks too good to be true. But we can't make the call without more information," he said. "Undoubtedly, the mainstream media will not look into this, Pfizer will remain silent and Polack will be unreachable for comment. The lack of transparency should be troubling to everyone. That is the one thing we can say for sure."
BigPharmaNews.com has more on the fraudulent practices of pharmaceutical companies like Pfizer.
Watch this presentation from entrepreneur and COVID-19 vaccine researcher Steve Kirsch as he lays out the evidence strongly suggesting Pfizer committed fraud during its vaccine trials.